Har Grover is an entrepreneur, investor, senior executive and strategist with over 30 years of experience in healthcare, life sciences and technology. Now the Executive Chairman of Scientus Pharma, he has worked with growth companies at all stages, from start-up to commercialization, to going public and growing through the $1 billion revenue mark. Har has helped companies enter new markets both in Canada and internationally – organically and through M&A, strategic alliances, and joint ventures.
Har was previously Co-Founder of CannScience Innovations as well as founder and managing director of Nucleus GC, a professional services and investment company in Toronto specializing in life sciences markets.
Har has served on several corporate and non-profit boards including Chair of Armour Therapeutics, Chair of Crohn’s and Colitis Canada, Board Director of Medworxx, Board Director of MedcannAccess. Har has an undergraduate degree in life sciences, and an MBA and also obtained professional CMC and ICD.D designations.
Rav Grover is a chartered accountant with significant experience in business advisory and development, having worked with a number of private and public companies over the last 25 years. He has been the lead M&A advisor on numerous transactions, structured a variety of debt instruments and equity raises, reverse takeovers and initial public offerings, as well as advising on an array of tax structures.
Rav was a Co-Founder of CannScience Innovations Inc. and has served on several corporate, not-for-profit and advisory boards.
Phillip brings over 25 years of investment banking, private equity and senior executive experience to Scientus Pharma. His extensive knowledge in private and public financing, mergers and acquisitions, and corporate development helps fuel the Company’s vision for growth. A chartered accountant, Phillip’s contributions and leadership extend to corporate strategy, business development and licensing, mergers and acquisitions, alliance management and investor relations.
Phillip is a former Co-Founder of CannScience Innovations Inc. and was the COO of a financial services firm with over $7.0 billion in assets under management.
Mark Fletcher has 30 years’ professional experience at the intersection of business, finance, and law.
He has: practiced corporate law focusing on mergers and acquisitions, corporate finance, securities law, and corporate governance; spent 14 years as General Counsel to a U.S.-listed (OTCQB, Nasdaq) biotechnology company; served over five years as Chief Executive Officer of a publicly-traded company; and, advised, and served as a member of, the Boards of Directors of private and public companies.